Background: Respiratory diseases remain among the top five leading causes of morbidity, with an incidence rate of 788.4 cases per 10,000 population in 2021. Among these, acute bronchitis accounts for 9.3%. According to international clinical guidelines for the diagnosis and treatment of adult acute bronchitis, symptoms usually resolve spontaneously within 1–3 weeks, but they considerably reduce the patient’s quality of life. Therefore, Colsaurin syrup, a new natural formulation with analgesic and anti-inflammatory effects, was clinically investigated to assess its efficacy and safety. The introduction of this domestically produced herbal medicine into clinical practice is expected to have both medical and socioeconomic significance by expanding the range of national pharmaceutical products. Aim: To evaluate the effect of Colsaurin syrup on the quality of life in adults diagnosed with acute bronchitis. Materials and Methods: This study was a randomized, double-blind, placebo-controlled clinical trial conducted among inpatients at Songinokhairkhan District General Hospital, Ulaanbaatar. Adult patients diagnosed with acute bronchitis (J20) who met the inclusion criteria and provided informed consent were enrolled. Participants were randomly assigned to either the Colsaurin or placebo group. Result: In the Bronchitis Severity Score (BBS) assessment, baseline mean scores indicated severe disease: 10.88±2.47 in the Colsaurin group and 10.67±2.16 in the placebo group. After treatment, scores decreased significantly to 3.50±1.41 (p<0.001) in the Colsaurin group and 5.00±2.24 (p=0.006) in the placebo group, indicating greater improvement in the Colsaurin-treated patients. In the Visual Analog Scale (VAS) assessment, the mean pre-treatment score for both groups was 7, corresponding to frequent cough, which decreased to 2 after treatment (p<0.05), representing a 28% reduction in coughing discomfort. In the Cough and Sputum Assessment Questionnaire (CASA-Q), the Colsaurin group showed a 3.25-point reduction after treatment, indicating a significant decrease in cough frequency and triggering factors (p<0.05). Conclusion 1. In patients diagnosed with acute bronchitis (J20), treatment with Colsaurin syrup reduced disease severity by 30% and alleviated cough-related discomfort by 28% compared to baseline. 2. Moreover, patients reported improved sleep quality and work capacity, reflecting an overall enhancement in quality of life. 3. No adverse effects were observed in the Colsaurin treatment group.

Background: Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin lymphoma of B-lymphocyte origin, characterized by an aggressive clinical course. Clinically, it most often presents with lymphadenopathy and “B symptoms,” including fever, night sweats, and weight loss. However, in some cases, the disease predominantly involves extranodal organs, such as the spleen, and may present with nonspecific manifestations, thereby posing a diagnostic challenge. Case presentation: A 36-year-old male patient presented with high-grade fever of unknown origin, dyspnea, generalized weakness, sweating, and a 7–8 kg weight loss over one month. Clinical evaluation and laboratory investigations revealed massive splenomegaly measuring 15 × 20 × 20 cm, progressive thrombocytopenia, anemia, and elevated C-reactive protein and lactate dehydrogenase levels. Diagnostic workup for infection, tuberculosis, viral infection, and autoimmune disease did not reveal findings sufficient to establish an alternative diagnosis. Because focal splenic lesions and suspected splenic infarction were identified, splenectomy was performed. Histopathological and immunohistochemical examination of the splenic tissue demonstrated CD20+, CD79a+, BCL2+, CD3−, CD8−, CD30−, and ALK− expression, confirming the final diagnosis of diffuse large B-cell lymphoma. Although DLBCL itself is a common form of non-Hodgkin lymphoma, this case is clinically rare and diagnostically challenging because it presented with predominant splenic involvement, massive splenomegaly measuring 15×20×20 cm, treatment-resistant fever, progressive thrombocytopenia, and imaging findings mimicking splenic infarction. Conclusion In patients presenting with fever of unknown origin that is resistant to treatment, massive splenomegaly, thrombocytopenia, elevated LDH, and increased inflammatory markers, lymphoproliferative disorders should be considered early in the differential diagnosis in addition to infectious causes. Histopathological and immunohistochemical examination play a crucial role in confirming the diagnosis.

Background: Atopic dermatitis is a chronic, relapsing inflammatory skin disorder in which immune dysregulation and skin barrier dysfunction play crucial roles, alongside neuroendocrine factors. Psychological stress influences the activity of the hypothalamic-pituitary-adrenal (HPA) axis, thereby altering cortisol secretion and inflammatory responses. However, the relationships among cortisol levels, neutrophil-to-lymphocyte ratio (NLR), psychological parameters, and disease severity remain insufficiently explored. Aim: To compare cortisol levels, neutrophil-to-lymphocyte ratio, and psychological parameters between adults with atopic dermatitis and healthy controls. Materials and Methods: A case-control study was conducted including 12 patients with atopic dermatitis and 12 healthy controls. Serum cortisol levels and complete blood counts (for NLR calculation) were assessed. Psychological status was evaluated using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7). Disease severity was measured using the SCORAD index. Statistical analyses included group comparisons and correlation analyses. Results: Cortisol levels in the atopic dermatitis group were significantly lower than those in the control group (p<0.001). Cortisol levels showed a significant negative correlation with SCORAD scores (r = -0.65, p = 0.021) and GAD-7 scores (r=-0.56, p=0.036). A negative correlation was also observed between disease duration and cortisol levels (r=-0.53, p=0.075), although this did not reach statistical significance. Conclusion Dysregulation of the HPA axis in atopic dermatitis, reflected by reduced cortisol levels, may be associated with increased disease severity and psychological stress. These findings highlight the importance of incorporating psychological assessment into the comprehensive management of atopic dermatitis.

Background: Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disorder of the hair follicle that predominantly affects areas rich in apocrine sweat glands, such as the axillae and groin. Clinically, it is characterized by painful nodules, abscess formation, sinus tract development, and scarring. Diagnosis is primarily based on clinical findings; however, due to limited awareness of the disease, it is often diagnosed at a late stage. Misdiagnosis and inappropriate management are common, leading to chronic disease progression. Consequently, HS significantly impairs quality of life through reduced work capacity, psychological distress, and social isolation. Disease severity is commonly assessed using the Hurley staging system and the Sartorius scoring system. We present a rare case of hidradenitis suppurativa encountered in dermatological practice. Case presentation A 35-year-old male patient (initials L.B.) presented with recurrent, painful lesions in both axillary regions associated with purulent discharge. The condition had persisted over a prolonged period with repeated exacerbations. The patient had attempted self-treatment at home without improvement and was subsequently admitted to the Department of Dermatology at the National Center for Dermatology with a diagnosis of DS: L73.2 (hidradenitis suppurativa). The patient was treated with systemic antibiotics (doxycycline and cefazolin), retinoids, supportive therapy, and topical treatment. In addition, intralesional triamcinolone injections were administered into active nodules, which proved effective in rapidly reducing inflammation, pain, and purulent discharge.

Background: Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease characterized by linear deposition of immunoglobulin A along the subepidermal basement membrane zone. Although it can occur in both children and adults, the disease in pediatric patients often requires careful consideration due to challenges in differential diagnosis and variability in treatment response. Dapsone is considered the first-line treatment; however, in some cases it may be unavailable, contraindicated, or associated with adverse effects, necessitating alternative therapeutic options. Case Presentation In this case report, we present the clinical features, diagnostic findings, treatment course, and outcomes of a 9-year-old girl diagnosed with LABD. The combination of colchicine and systemic corticosteroids resulted in marked clinical improvement, suggesting that this regimen may be a potential alternative treatment for LABD.

BACKGROUND. Heart failure is the leading cause of the death among non-communicable diseases. Heart failure is a fatal disease that once its clinical symptoms appeared, five years of survival rate is 50-75%. Chronic heart failures are the main risk factors arterial hypertension, diabetes, obesity and dyslipidemia Thus, early diagnosis before its symptoms are presented and treatment with close monitoring is the most rational and effective approach for decreasing heart failure diseases and deaths caused by it. OBJECTIVE. To determine the level of NT-pro BNP in people with high risk of chronic heart failure and assess its results. METHODS. We conducted hospital-based descriptive study at State Second Central Hospital and Bayanzurkh District Medical Center. Total of 100 participants aged from 35 to 64 who had no symptom of chronic heart failure however with high risk were recruited in this study. Based on the document entitled “Heart failure prevention 2008” of the American Heart Association, old age, arterial hypertension, diabetes mellitus, heart attack and obesity were considered as higher risks of heart failure. Risk factors of heart failure were estimated by questionnaire and physical examination. The level of NT-pro BNP in plasma was determined using FIA8000 analyzer. According to the guideline produced by the European Society of Cardiology in 2016, result of the testing is considered “positive” when NT-pro BNP is higher than 125 pg/ml. Risk factors of chronic heart failure were studied in comparison with two groups which were NT-pro BNP positive and negative results and their statistically significant difference were determined. RESULTS. Of 87 participants, 51 (51%) were female and 49(49%) were male. Half of the participants (51%) were aged between 55-64. Arterial hypertension was determined in 88% of the participant, 38% were overdose drink of alcohol, therefore 55% were 1,2,3 levels obesity and 36% were diabetic. When determining the NT-pro BNP level, in 34 cases (34%) were positive. Hence, 31% of the people with arterial hypertension, 9% of the people overdose drink with alcohol, 20% of the people with obesity, 12% of the people with diabetes showed positive results of NT-pro BNP. When studying the risk factors of chronic heart failure of the compared two groups of NT-pro BNP positive and negative results, statistically significant difference (p<0.05) was increased of the with arterial hypertension and obesity. CONCLUSION. NT-pro BNP is the arterial hypertension and obesity which is increasing for people compared to the other risking factors